Showing posts with label #proteinsummit. Show all posts
Showing posts with label #proteinsummit. Show all posts

Tuesday, May 3, 2016

Preparing for future bioprocessing challenges with the Cellca CHO Expression Platform

Therapeutic protein development and production is a very technically challenging, time consuming and expensive endeavor.

What are some of the challenges? There are numerous critical decisions that must be made with regard to mammalian cell line choice (CHO, NS0, etc.), appropriate gene and marker expression systems, cell culture medium and feed optimization, clone selection and scale-up strategies. Biopharmaceutical developers should be careful to choose options which deliver the following:

• Maximum protein titer
• Scalability (5L – 1000L)
• Long-term Stability
• Cost effectiveness
• Shortened development timelines
• No burdensome IP concerns

Why is it important and critical to understand these challenges? There are considerable economic considerations to be made; one should maximize financial budgets by minimizing expenditures on equipment and technologies required for in-house development and characterization of the therapeutic protein. It’s important to make efficient and productive investments in R&D; technology and process development requires highly trained and expert staff. There are also commercial or market considerations which will affect return on investments; to maximize IP and patent life the therapeutic protein must be developed and commercialized as quickly as possible to gain maximum market share in a highly competitive environment. First to market is paramount for biosimilar developers.

How has the CRO industry responded? “Turn-key” cell line development and bioanalytical testing CROs are currently open for business and accessible for outsourcing nearly all upstream, downstream and biomolecular analytical activities. Sartorius Stedim Biotech offer the most comprehensive, scalable and unique bioprocess portfolio to support Biosimilar development and manufacturing. With Sartorius Stedim Biotechs’ recent acquisition of Cellca (cell line development) and BioOutsource (bioanalytical and biosafety testing), there is now established a fully functional, and integrated CRO uniquely positioned to support clients development programs across the entire product lifecycle.

The result of outsourcing biopharmaceutical development and production to experienced CROs will have major positive implications for shortening the time to commercialization at significantly reduced costs.

To learn more about the industry leading Cellca CLD platform which delivers stable, high titre clones, (95% of projects have delivered titres >3.0g/litre) in a proven scalable fed batch manufacturing process in a cost and time efficient manner please join our talk by Dr. Brian Wendelburg at IBC Cell Line Development & Engineering Conference, San Francisco, 14th June at 1.25pm.



Author Bio:


Dr. Brian Wendelburg received his Ph.D. in Molecular Biophysics from the Institute of Molecular Biophysics at Florida State University. He then completed his postdoctoral training at the University of North Carolina’s Lineberger Comprehensive Cancer Center. His professional career has involved diverse roles in sales and business development activities at leading Biotech companies such as Cepheid, Affymetrix and Miltenyi Biotec where he gained a strong technical background in genomics, proteomics and cell and gene therapy applications. He joined the Sartorius-Stedim Biotech team in the spring of 2016 and is currently Sr. Field Marketing Manager for the BioOutsource and Cellca divisions.


Share this article with your social network, just click below to share now!


Monday, April 18, 2016

The Next Generation Protein Therapeutics Summit: Earn a complimentary pass as a Guest Blogger!

Earn a complimentary all-access pass to The Next Generation Protein Therapeutics Summit by serving as a Guest Blogger at the event. As a Guest Blogger, you’ll have access to the Next Generation Protein Therapeutics, and the co-located Cell Line Development & Engineering, and Bioconjugates: From Targets to Therapeutics events’ comprehensive agenda attracting the best insights from around the world, right in San Francisco, California in June.





The Next Generation Protein Therapeutics Summit
and the co-located 
Bioconjugates: From Targets to Therapeutics and Cell Line Development & Engineering
June 13 - 15, 2016
Parc 55 Hotel, San Francisco, CA


The Next Generation Protein Therapeutics Summit's image depicts Nanobody protein therapeutic molecule

We are looking for an industry expert with interest in the following topics:


• Speed of discovery and development
• Alternative administration routes
• Potency and payload capacity
• New potential targets in cancer
• Half-life
• Robustness of discovery and preclinical development of bispecific antibodies
• Generation of human bispecific antibodies
• Efficiency of CMC development
• Development of large scale, high yield and manufacturing process

• High-Throughput Platforms for Cell Line Development
• Advances in Host Cell Engineering
• Improving Processes and Product Quality
• Improving Biosimilarity
• Assuring Clonality and Stability
• Innovations in Alternative Expression Systems and Novel Host Cell Lines
• Cell Line Development and Modification for Novel Modalities 
• Genome Editing in CHO cells
• Cell Line Development and Modification for Difficult-to-Express Proteins
• Manufacturing Assessment Strategies
• Understanding CHO Metabolisms

• Intellectual Property and Linker Payloads 
• Progress in Combination Therapies 
• Breakthrough Discoveries and Advances in ADCs
• Analytical and Characterization Strategies 
• Eliminating Heterogeneity: Advancements in Site-Specific Conjugation 
• Innovations in ADC Design and Development
• Regulatory Considerations for ADCs 
• From Discovery to Commercialization: Readiness for Manufacturing & Commercialization
• Perfecting the Chemistry Behind Conjugation 
• Conjugate Vaccines and Novel Conjugate Technologies

...and who would like to learn more about protein therapeutics!

The premise is to provide protein therapeutics related articles, whitepapers, and overall original content with a strong focus on the whole protein engineering & design industry.
What You get is:

• FREE pass to the conference (valued up to $2,999.00);
• Access to extensive social learning activities;
• Exclusive admission to a networking community in the industry of your interest!

You also have a chance to GAIN exposure through our blog with over 2000 unique visitors monthly and more than 20 related LinkedIn groups with over 65,000 subscribers combined!

Learn more about the The Next Generation Protein Therapeutics Summit event by visiting our website.

Interested & want to learn more about this opportunity? Please contact Ksenia Newton at knewton@iirusa.com. Feel free to share your short biography, links to your blog or writing samples, along with a few sentences about why we should choose you to become the Guest Blogger for the Next Generation Protein Therapeutics Summit 2016!
We hope to have you join us in San Francisco!

* Guest Bloggers are responsible for their own travel and lodging.

* All content is subject to IBC approval.

Stay tuned: 

#ProteinSummit
Visit the website: http://bit.ly/208zLVP
Future of Biopharma Blog http://futurebiopharma.blogspot.com/


Share this article with your social network, just click below to share now!